Manuscript title: Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal

patients with COVID-19

Qiang Zeng, MD[#], Gang Huang, MD[#], Yong-zhe Li, MD[#], Guoqiang Xu, PhD, Sheng-yong Dong,

MD, Tian-yu Zhong, MD, Zong-tao Chen, MD, Yang Xu, MD, PhD[*]

Authors' name and affiliations:

Chinese PLA General Hospital, Beijing, China (Q. Zeng, S.Y. Dong); Shanghai University of

Medicine and Health Sciences, Shanghai, China (G. Huang, Y. Xu); Jiangsu Key Laboratory of

Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China

(G. Xu); First Affiliated Hospital, Gannan Medical University, Ganzhou, China (T.Y. Zhong); The

first affiliated Hospital, Army Medical University, Chongqing, China (Z.T. Chen); Department of

Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China (Y.Z. Li).

* Contact information for the corresponding author:

Yang Xu, MD, PhD, Director

Laboratory of Special Diagnosis

Shanghai University of Medicine and Health Sciences

Shanghai 201318, China

E-mail: yxu1627@126.com

Highlights

● **The immune system and function have gradually remodeled and declined with age**

● **SARS-CoV-2 specific immunity has declined with age in fatal cases**

● **SARS-CoV-2 specific immunity is associated with survival time in fatal cases**

● **The loss expansion of SARS-CoV-2 specific immunity could be expanded *in vitro***

● **A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and**

prolonged SARS-CoV-2 exposure predicted fatal outcomes

42   **Keywords**

43   CD4; CD8; COVID-19; Expansion; IFNγ; SARS-CoV-2 specific immunity; SARS-CoV-2; T cells

ABSTRACT

The dynamic immunological characteristics of COVID-19 patients are essential for clinicians to understand the disease progression. Our data showed that the immune system and function have gradually remodeled and declined with age from 16-91 years old in 25,239 healthy controls. Analyzing the relationship between the number of lymphocytes and age showed that lymphocytes and subsets tended to decline with age significantly, whereas, the number of natural killer cells tended to increase with age significantly. SARS-CoV-2 specific immunity has declined with age in fatal cases. Furthermore, SARS-CoV-2 specific immunity is associated with survival time in fatal cases. The loss expansion of SARS-CoV-2 specific immunity could be expanded *in vitro*. A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. Our findings have provided a basis for further analysis of SARS-CoV-2 specific immunity and understanding the pathogenesis of fatal COVID-19 patients.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) pandemic leads to severe illness, life-threatening

complications, and death, especially in high-risk groups such as elderly people and individuals

with comorbidities[1-7]. However, information on immunological characteristics in the assessment

of COVID-19 for frontline clinicians is limited. The objective of this study is to explore the

dynamic immunological characteristics as the disease progresses.

In January, 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was

identified in samples of bronchoalveolar lavage fluid from patients in Wuhan, China, and was

confirmed as the cause of the SARS-CoV-2 pneumonia[1,2]. Full-genome sequencing and

phylogenic analysis indicated that SARS-CoV-2 is a distinct clade from the betacoronaviruses

associated with human SARS and Middle East respiratory syndrome (MERS)[1,2].

COVID-19 has spread rapidly since it was first identified in Wuhan and has been shown to have a

wide spectrum of severity. Recently, a report shows that SARS-CoV and SARS-CoV-2 shared the

same functional host-cell receptor, angiotensin-converting enzyme 2 (ACE2)[8]. Furthermore,

SARS-CoV-2 binds to ACE2 receptors in 10-20 fold higher affinity than SARS-CoV binds to the

same receptors[8]. The receptor binding domain is recognized by the extracellular peptidase domain

of ACE2 mainly through polar residues, which provide important insights into the molecular basis

for coronavirus recognition and infection[9]. Since ACE2 receptors on lung alveolar epithelial cells

and enterocytes of the small intestine are highly expressed, lung alveolar epithelial cells or

enterocytes of the small intestine may be an important source of infection[10].

According to World Health Organization (WHO) interim guidance on January 12, 2020,

SARS-CoV-2 infection is classified as asymptomatic, mild, severe, and critical cases of

pneumonia (acute respiratory distress syndrome [ARDS], sepsis, septic shock). Severe cases of

pneumonia are defined as patients with respiratory rate > 30 breaths/min, severe respiratory

distress, or peripheral capillary oxygen saturation < 90% on room air[11]. Asymptomatic cases have

been reported in China and Germany[12,13]. Huang et al.[2] first reported 41 cases of SARS-CoV-2

pneumonia in which most patients had a history of exposure to Huanan Seafood Wholesale

Market. Organ dysfunction (shock, ARDS, acute cardiac injury, and acute kidney injury, etc.) and

death can occur in severe or critical cases. Guan et al.[3] reported findings from 1,099 cases of

SARS-CoV-2 pneumonia and the results suggested that the SARS-CoV-2 infection clustered

within groups of people in close contact, and was more likely to affect the old with comorbidities.

However, there is no pre-existing antibody-mediated immunity to SARS-CoV-2 at the population

level, leading to more than half million deaths and 10 millions of infections which have been

reported worldwide as of June 29, 2020[14].

The disease severity is associated with immune dysregulation, for example, dysregulation of T

cells, or associated with macrophage activation syndrome[15-21]. Grifoni et al.[22] reported

SARS-CoV-2-specific CD4 and CD8 T cells responses in 20 recovery cases of COVID-19. Using

multiple experimental approaches, SARS-CoV-2-specific CD4 T cell and antibody responses were

observed in all COVID-19 patients and SARS-CoV-2-specific CD8 T cell responses were seen in

most COVID-19 patients. All of the patients had SARS-CoV-2-specific CD4 T cells that

recognized the virus's spike protein, and 70% of them had SARS-CoV-2-specific CD8 T cells that

responded to the same protein. The identification of strong T cell responses in recovered

COVID-19 patients promotes further study in designing vaccines to induce T cell responses. Ni et

al.[18] also observed SARS-CoV-2-specific humoral and cellular immunity in 14 convalescent

patients. However, to the best of our knowledge, SARS-CoV-2-specific CD4 and CD8 T cell

responses in fatal cases of COVID-19 were not reported. Furthermore, understanding the key

immune mechanisms to recover from novel SARS-CoV-2 exposure is an urgent need.

It is important to understand the key risk factors of critical patients who died. We hypothesize that

lethal COVID-19 disease would be associated with immune dysregulation and loss expansion of

SARS-CoV-2-specific immunity. Here, we analyzed dynamic immunological characteristics in

fatal COVID-19 patients in a unique longitudinal cohort of samples.

RESULTS

The immune system and function have gradually remodeled and declined with age in 25,239

healthy controls

The relationship between the number of lymphocytes and subsets and age showed that

lymphocytes and subsets except natural killer (NK) cells tended to decline with age significantly

(Figure 1A-E, Spearman R = –[range, 0.08978-0.1950], $P < 0.0001$). However, the relationship

between NK cells and age showed that the number of NK cells tended to increase with age (Figure

1F, Spearman R = 0.1188, $P < 0.0001$) significantly, suggesting that NK cells, a component of the

innate immune system, expanded with age.

SARS-CoV-2 specific immunity has declined with age in fatal COVID-19 patients

The relationship between SARS-CoV-2 specific immunity and age showed that SARS-CoV-2

specific immunity tended to decline with age (Figure 2A-C). However, the relationship between

SARS-CoV-2 virus load and age showed that the virus load tended to increase with age (Figure

2D).

The ability to expand SARS-CoV-2 specific interferon gamma (IFNγ)+CD4+ T cells (Figure 2A,

Spearman R = -0.8020, $P < 0.0001$) and IFNγ+CD8+ T cells (Figure 2B, Spearman R = -0.8028,

$P < 0.0001$) was significantly inversely related to age. It suggested that the elderly was low in

expansion ability of SARS-CoV-2 specific T cell immunity, so it was easy to turn into severe

illness, which was an important risk factor for mortality in the elderly. SARS-CoV-2 specific

humoral immunity (Figure 2C, Spearman R = -0.2671, $P = 0.0254$) was also inversely related to

age. However, this relationship was weaker than that of SARS-CoV-2 specific T cell immunity.

SARS-CoV-2 viral load was directly proportional to age, which was significant (Figure 2D,

Spearman R = 0.4780, $P < 0.0001$). It suggested that the elderly were easily infected by the virus

or the patient had a higher viral load in the body.

SARS-CoV-2 specific immunity is associated with survival time in fatal COVID-19 patients

The relationship between SARS-CoV-2 specific immunity and survival time showed that as the

survival time increases, SARS-CoV-2 specific immunity tended to rise. However, the relationship

between virus load and survival time showed that the virus load tended to decrease as the survival

time increases (Figure 3).

The correlation between SARS-CoV-2 specific IFNγ+CD4+ T cells (Figure 3A, Spearman R =

0.7655, $P < 0.0001$) and IFNγ+CD8+ T cells (Figure 3B, Spearman R = 0.7623, $P < 0.0001$) and

survival time was relatively strong, and significantly correlated with survival time, suggesting that

patient survival time depended on the expansion ability of SARS-CoV-2 specific T cell immunity.

The aggregated data for 4 weeks showed that SARS-CoV-2 specific humoral immunity was

related to survival time significantly (Figure 3C, Spearman R = 0.7924, P < 0.0001).

SARS-CoV-2 viral load was inversely proportional to survival time significantly (Figure 3D,

Spearman R = -0.4730, P < 0.0001). It suggested that the higher the viral load of SARS-CoV-2,

the shorter the survival time of patients. Therefore, controlling the replication of the virus might

prolong the survival time of patients.

There was no significant difference in the frequency of SARS-CoV-2 specific IFNγ+CD4+ T cells

(Figure 4A) between the first week and the second week. However, there were significant

differences between the first week and the third or fourth week, suggesting that SARS-CoV-2

specific IFNγ+CD4+ T cells began to expand in the third week significantly (Figure 4A). There

was no significant difference in the frequency of SARS-CoV-2 specific IFNγ+CD8+ T cells

between the first week and the second, third, or fourth week, indicating that the expansion of

specific CD8 T cells were lost (Figure 4B). There was a significant difference between the titer of

specific IgG antibodies in the first week and the second week. Compared to the first week, the IgG

titer in week 2-4 continued to show significant differences, suggesting that SARS-CoV-2 specific

antibodies began to expand in the second week, but the antibody titer was low (Figure 4C). There

was a significant difference between the viral load from week 1 to week 4 (Figure 4D), suggesting

that SARS-CoV-2 specific immunity could clear SARS-CoV-2 replication in fatal cases. However,

the SARS-CoV-2 specific immunity was unable to clear all SARS-CoV-2 in fatal cases. The mean

viral load was 6.7 x 10^4 copies/mL at week 3, indicating the presence of persistent SARS-CoV-2

infection.

The loss expansion of SARS-CoV-2 specific immunity in fatal cases could be expanded *in*

vitro

From the above results, it can be known that the key factor was the loss expansion of

SARS-CoV-2 specific humoral and cellular immunity and the virus cannot be eliminated from the

body in fatal cases. Since the expansion of SARS-CoV-2 specific immunity started from the first

2-3 weeks, we chose PMBCs in the third week for the expansion experiment *in vitro*. Our data

showed that these PBMCs could be expanded *in vitro*. After the expansion, SARS-CoV-2 specific

IFNγ+CD4+ T cells and IFNγ+CD8+ T cells increased significantly (Figure 5). It suggested that

the SARS-CoV-2 specific immunity of these 21 fatal patients lost their expansion at week 3, but

the expansion of SARS-CoV-2 specific cellular immunity could be recovered *in vitro* experiment

(Figure 5).

A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and prolonged

SARS-CoV-2 exposure predicted fatal outcomes

There was significant correlation between SARS-CoV-2 specific IFNγ+CD4+ T cells (Figure 6A,

Spearman R = 0.4537, *P* < 0.0001) and IFNγ+CD8+ T cells (Figure 6B, Spearman R = 0.3721, *P*

= 0.0002) and SARS-CoV-2 specific humoral immunity.

SARS-CoV-2 specific IFNγ+CD4+ T cells (Figure 7A, Spearman R = -0.4784, *P* < 0.0001) and

IFNγ+CD8+ T cells (Figure 7B, Spearman R = -0.4609, *P* < 0.0001) inversely correlated with

SARS-CoV-2 viral load significantly, suggesting that SARS-CoV-2 specific T cell immunity plays

a leading role in virus clearance. However, the frequency of SARS-CoV-2 specific T cells was

significantly lower than that of survival patients with COVID-19 (Figure 9A, 9B), suggesting that

loss expansion of SARS-CoV-2 specific cellular immunity in fatal cases.

SARS-CoV-2 specific humoral immunity inversely correlated with SARS-CoV-2 viral load

significantly, suggesting that SARS-CoV-2 specific humoral immunity played a role in virus

clearance (Figure 8). However, the R number of SARS-CoV-2 specific humoral immunity was

smaller than that of SARS-CoV-2 specific T cell immunity (Figure 7, Figure 8), suggesting that

SARS-CoV-2 specific T cell immunity might play a major role in virus clearance in fatal cases. In

addition, the IgG titer was significantly lower than that of survival patients with COVID-19

(Figure 9C), suggesting that loss expansion of SARS-CoV-2 specific humoral immunity in fatal

cases.

However, the SARS-CoV-2 specific immunity was unable to clear SARS-CoV-2 in fatal cases. All

patients were detected positive viral load before death, suggesting that prolonged SARS-CoV-2

exposure predicted fatal outcomes (Figure 4D).

DISCUSSION

The extent of lymphopenia in patients admitted to the intensive care unit correlates with

COVID-19 severity and mortality[23-26]. Therefore, studies of the immune system and function in

healthy controls are important to understand whether the immune system and function is related to

age. Our data showed that the immune system and function have gradually remodeled and

declined with age in 25,239 healthy controls.

Channappanavar et al.[27] reported that SARS-CoV-specific memory CD8 T cells persisted for up to

6 years after SARS-CoV infection. When challenge with a lethal dose of SARS-CoV,

virus-specific memory CD8 T cells efficiently produced IFNγ, tumor necrosis factor α (TNF-α),

etc. and reduced lung viral load. Next, we tried to understand whether SARS-CoV-2 specific

immunity is associated with age in those fatal patients with COVID-19. Our data suggested that

SARS-CoV-2 specific immunity has declined with age in COVID-19 patients.

Levels of lymphocytes and lymphocyte subsets are of great importance to keep the immune

system working. Usually viral infection, immunodeficiency diseases, and other infectious diseases

lead to abnormal changes in the levels of lymphocyte subsets[16]. Although SARS-CoV-2 has been

identified as the causative agent of COVID-19, the mechanism by which SARS-CoV-2 impacts

the human immune system is still unclear[16].

Grifoni et al.[22] reported SARS-CoV-2-specific CD4 and CD8 T cells responses in 20 recovery

cases of COVID-19. SARS-CoV-2-specific CD4 T cell and antibody responses were observed in

all COVID-19 patients and SARS-CoV-2-specific CD8 T cell responses were seen in most

COVID-19 patients. Ni et al.[18] also observed SARS-CoV-2-specific humoral and cellular

immunity in 14 convalescent patients. We explored whether SARS-CoV-2 specific immunity is

associated with survival time in those fatal patients with COVID-19. Our data showed that

SARS-CoV-2 specific immunity was associated with survival time in COVID-19 patients. Our

results were consistent with previous reports[18,22].

From the above results, it can be known that the key factor was the loss expansion of

SARS-CoV-2 specific humoral and cellular immunity and the virus cannot be eliminated from the

body in fatal cases. We tried to understand whether the loss expansion of SARS-CoV-2 specific

immunity in fatal cases could be expanded *in vitro*. Since the expansion of SARS-CoV-2 specific

immunity started from the first 2-3 weeks, we chose PMBCs in the third week for the expansion

experiment *in vitro*. Our data showed that these PBMCs could be expanded *in vitro*. After the

expansion, SARS-CoV-2 specific IFNγ+CD4+ T cells and IFNγ+CD8+ T cells increased

significantly. It suggested that the SARS-CoV-2 specific immunity of these fatal patients lost their

expansion, but the expansion of SARS-CoV-2 specific cellular immunity could be recovered *in*

vitro experiment.

Our data indicated that a concurrent decline in SARS-CoV-2 specific cellular and humoral

immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. First, the immune

system and function have gradually remodeled and declined with age in healthy controls.

Therefore, the elderly are susceptible to the SARS-CoV-2. Second, our data showed that

SARS-CoV-2 specific immunity has declined with age in COVID-19 patients. Therefore, the

elderly easily turned from mild to severe SARS-CoV-2 infections. Those results have explained

that the elderly is a risk factor for poor outcomes. Third, our data further showed that

SARS-CoV-2 specific immunity is associated with survival time in COVID-19 patients. The

correlation between SARS-CoV-2 specific IFNγ+CD4+ T cells and IFNγ+CD8+ T cells and

survival time was relatively strong, and significantly correlated with survival time, suggesting that

patient survival time depended on the expansion ability of SARS-CoV-2 specific T cell immunity.

The aggregated data for 4 weeks showed that SARS-CoV-2 specific humoral immunity was

related to survival time. SARS-CoV-2 viral load was inversely proportional to survival time

significantly. It suggested that the higher the viral load of SARS-CoV-2, the shorter the survival

time of patients. Therefore, controlling the replication of the virus might prolong the survival time

of patients. Finally, we observed that a concurrent decline in SARS-CoV-2 specific cellular and

humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. There was

significant correlation between SARS-CoV-2 specific T cell immunity and SARS-CoV-2 specific

humoral immunity. The frequency of SARS-CoV-2 specific T cells and titer of IgG were much

lower than that of survival patients with COVID-19 and there were high viral load in the course of

the disease, indicating that the persistent SARS-CoV-2 infection and the loss expansion of

SARS-CoV-2 specific immunity.

Acknowledgments

The work was supported in part by the National Natural Science Foundation of China (Grant No.

81830052 and 81530053).

Author contributions

[#]Drs. Q Zeng, G Huang and YZ Li contributed equally to this article and share first authorship.

[*] Correspondence to Dr. Y Xu.

Q Zeng, G Huang and YZ Li contributed to study design, data interpretation, and manuscript

drafting. GX, ZTC, ZTC contributed to data analysis, figure preparation, the literature search, and

manuscript drafting. SYD and GX contributed to performed experiments, data collection, data

analysis, and figure preparation. YX contributed to study design and reviewed the final draft. All

authors read and approved the manuscript.

Competing interests statement

We declare no competing interests.

References

1.   Zhu, N.*, et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl.J.*

Med. **382**, 727-733 (2020).

2.   Huang, C.*, et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,

China. *Lancet (London, England)* **395**, 497-506 (2020).

3.   Guan, W.J.*, et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl.J.*

Med. **382**, 1708-1720 (2020).

4.   Li, Q.*, et al.* Early transmission dynamics in Wuhan, China, of novel coronavirus-infected

pneumonia. *N. Engl.J. Med.* **382**, 1199-1207 (2020).

5.   Wang, D.*, et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel

coronavirus-infected pneumonia in Wuhan, China. *JAMA* **323**, 1061-1069 (2020).

6.   Zhou, F.*, et al.* Clinical course and risk factors for mortality of adult in patients with

COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)* **395**,

1054-1062 (2020).

7.   Wu, C.*, et al.* Risk factors associated with acute respiratory distress syndrome and death in

patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern. Med.*, doi:

10.1001/jamainternmed.2020.0994 (2020).

8.   Wrapp, D.*, et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Science (New York, N.Y.) **367**, 1260-1263 (2020).

9.   Yan, R.*, et al.* Structural basis for the recognition of SARS-CoV-2 by full-length human

ACE2. *Science (New York, N.Y.)* **367**, 1444-1448 (2020).

10. Hamming, I*., et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS

coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **203**, 631-637

(2004).

11. World Health Organization. Clinical management of severe acute respiratory infection when

novel coronavirus (nCoV) infection is suspected. *Interim guidance on January 12, 2020*

(accessed February 15), https://apps.who.int/iris/handle/10665/330854 (2020).

12. Pan, X*., et al.* Asymptomatic cases in a family cluster with SARS-CoV-2 infection. *Lancet*

Infect. Dis. **20**, 410-411 (2020).

13. Rothe, C*., et al.* Transmission of 2019-nCoV infection from an asymptomatic contact in

Germany. *N. Engl.J. Med.* **382**, 970-971 (2020).

14. WHO. Rolling updates on coronavirus disease (COVID-19). .

https://www.who.int/emergencies/diseases/novel-coronavirus-2019 *(accessed June 29, 2020)*

(2020).

15. Xu, Z*., et al.* Pathological findings of COVID-19 associated with acute respiratory distress

syndrome. *Lancet Respir. Med.* **8**, 420-422 (2020).

16. Vabret, N*., et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**,

910-941 (2020).

17. Diao, B*., et al.* Reduction and functional exhaustion of T cells in patients with coronavirus

disease 2019 (COVID-19). *Front. Immunol*. **11**, 827 (2020).

18. Ni, L*., et al.* Detection of SARS-CoV-2-specific humoral and cellular immunity in

COVID-19 convalescent individuals. *Immunity* **52**, 971-977.e973 (2020).

19. Giamarellos-Bourboulis, E.J*., et al.* Complex immune dysregulation in COVID-19 patients

with severe respiratory failure. *Cell Host Microbe* **27**, 992-1000.e1003 (2020).

20. Day, C.L*., et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion

and disease progression. *Nature* **443**, 350-354 (2006).

21. Trautmann, L*., et al.* Upregulation of PD-1 expression on HIV-specific CD8[+] T cells leads to

reversible immune dysfunction. *Nat. Med*. **12**, 1198-1202 (2006).

22. Grifoni, A*., et al.* Targets of T cell responses to SARS-CoV-2 coronavirus in humans with

COVID-19 disease and unexposed individuals. *Cell* **181**, 1489-1501.e1415 (2020).

23. Chen, G*., et al.* Clinical and immunological features of severe and moderate coronavirus

disease 2019. *J. Clin. Invest*.   **130**, 2620-2629 (2020).

24. Liu, J*., et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in

the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine* **55**, 102763 (2020).

25. Tan, L*., et al.* Lymphopenia predicts disease severity of COVID-19: a descriptive and

predictive study. *Signal. Transduct. Target. Ther*. **5**, 33 (2020).

26. Wang, F*., et al.* Characteristics of peripheral lymphocyte subset alteration in COVID-19

pneumonia. *J. Infect. Dis*. **221**, 1762-1769 (2020).

27. Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D.K. & Perlman, S. Virus-specific

memory CD8 T cells provide substantial protection from lethal severe acute respiratory

syndrome coronavirus infection. *J. Virol*. **88**, 11034-11044 (2014).

Figures and Legends

Figure 1. Dynamic distribution of lymphocytes and subsets related to age in 25,239 health controls.

We enrolled laboratory data from 25,239 health controls aged from 16-91 years old in November

2017 and November 2019 from health check up before the COVID-19 pandemic.

Figure 2. Dynamic distribution of SARS-CoV-2 specific immunity and viral load related to age in

fatal cases.

Figure 3. Dynamic distribution of SARS-CoV-2 specific immunity and viral load related to

survival time in fatal cases.

Figure 4. Dynamic characteristics of SARS-CoV-2 specific immunity and viral load in fatal cases.

ns, $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

Figure 5. PBMCs of 21 fatal cases at week 3 were stimulated with SARS-CoV-2 Spike

glycoprotein peptide pools (SPs). The graph showed the percentage of SARS-CoV-2 specific

IFNγ+CD4+T cells (A) and SARS-CoV-2 specific IFNγ+CD8+ T cells (B) reactive to the SPs

directly *ex vivo* (w/o expansion) and after *in vitro* expansion (expansion). **, $P=0.0017$; ****,

$P<0.0001$.

Figure 6. SARS-CoV-2 specific T cell immunity (IFNγ+CD8+ and IFNγ+CD4+) did not correlate

with SARS-CoV-2 specific humoral immunity.

Figure 7. SARS-CoV-2 specific T cell immunity (IFNγ+CD8+ and IFNγ+CD4+) inversely

correlated with SARS-CoV-2 viral load.

Figure 8. SARS-CoV-2 specific humoral immunity（IgG）inversely correlated with SARS-CoV-2

viral load.

Figure 9. SARS-CoV-2 specific immunity of 21 fatal cases and 18 survival cases at week 3 were

compared. The graph showed the percentage of SARS-CoV-2 specific IFNγ+CD4+T cells (A),

SARS-CoV-2 specific IFNγ+CD8+ T cells (B) and IgG titers (C). ****, $P < 0.0001$.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

A

Spearman（R = 0.4537, *P* < 0.0001)

IgG titer

B

Spearman（R = 0.3721, *P* = 0.0002)

IgG titer

Figure 6

Figure 7

Figure 8

Figure 9

422   **Table S1. Demographic characteristics of 35 fatal patients with COVID-19 on admission**

Characteristics	Patients
Age, Median (IRQ), years	64.0 (45.0-73.0)
Gender	
Male	24 (68.6%)
Female	11 (31.4%)
Comorbidities	
Hypertension	11 (31.4%)
Cardiovascular diseases	7 (20.0%)
Diabetes	6 (17.1%)
Main symptoms	
Fever	30 (85.7%)
Cough	18 (51.4%)
Fatigue	6 (17.1%)

Figure S1. A representative flow cytometry gating strategy.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Study Design and Participants

This retrospective study was conducted at Chinese PLA General Hospital, Peking Union Medical

College Hospital, the First Affiliated Hospital, and affiliated hospitals of Shanghai University of

Medicine and Health Sciences. Chinese PLA General Hospital and Peking Union Medical College

Hospital are the largest clinical research hospitals in China. Demographic characteristics of 35

fatal patients with COVID-19 on admission were listed in Table S1. The 18 severe or critical cases

(matched by age and sex) that survived were enrolled for comparison. This case series was

approved by the institutional ethics board of Chinese PLA General Hospital (#2020-111), Peking

Union Medical College Hospital (#ZS-1830), The First Affiliated Hospital (#KY2020046), and

Shanghai University of Medicine and Health Sciences (#2019-LCHZ-18-20190507). Written

informed consent was obtained from healthy controls and waived to COVID-19 patients due to the

rapid emergence of this infectious disease. Identification of hypertensive patients was achieved by

reviewing and analyzing available electronic medical records and patient care resources. Clinical

outcomes (discharge, mortality, and recovery, etc.) were monitored and all clinical recovery

hypertensive patients meet the following criteria: body temperature returned to normal for more

than 3 days, respiratory symptoms improved significantly, and lung imaging showed significant

improvement.

METHOD DETAILS

Cell preparation

Whole blood was centrifuged for 15 min at 1800 rpm to separate the cellular fraction and plasma.

The plasma was then carefully removed from the cell pellet and stored at -20°C. Peripheral blood

mononuclear cells (PBMCs) were isolated using Ficoll-Paque PLUS density gradients (GE

Healthcare Life Sciences, USA) according to the manufacturer's instructions. Isolated PBMCs

were either studied directly or cryopreserved in cell recovery media containing 10% DMSO

(Gibco, USA), supplemented with 10% heat inactivated fetal bovine serum and stored in liquid

nitrogen until used in the assays. Cryopreserved PBMCs were thawed by diluting them in 10 mL

complete RPMI 1640 with 5% human AB serum (Gemini Bioproducts, USA) in the presence of

benzonase (final concentration at 50 U/mL) before an experiment.

SARS-CoV-2 Spike glycoprotein peptide pools

SARS-CoV-2 Spike glycoprotein peptide pools (SPs) were from Genscript Biotech, USA. SPs

include 316 peptides (delivered in two subpools of 158 peptides) derived from a peptide scan (15

mers with 11 amino acid overlap) through the entire Spike glycoprotein of SARS-CoV-2.

Expansion of PBMCs *in vitro*

20% of PBMCs were pulsed with 10 μg/mL of the SPs for 1 hour at 37 °C, subsequently washed,

and cocultured with the remaining cells in AIM-V medium (Gibco; Thermo Fisher Scientific,

USA) supplemented with 2% AB human serum (Gibco; Thermo Fisher Scientific, USA). PBMCs

were cultured for 7 days in the presence of 20 U/mL of recombinant IL-2 (R&D Systems, USA).

Intracellular cytokine staining (ICS) assay

PBMCs were first stimulated with or without SPs (2 μg /mL) for 3 h at 37°C, then brefeldin A (10

μg/mL, Sigma-Aldrich, USA) was added to cultures to enable intracellular proteins to accumulate

in all stimulations. PBMCs were stimulated RPMI medium containing 10% FCS as a negative

control. After incubation for a total of 6 h, the cells were washed, fixed, permeabilized using

fixation/permeablization solution kit (BD Biosciences, USA) and blocked with FcR blocking

reagent (Meltenyi Biotec, USA) for 30 min at 4 °C to reduce nonspecific binding of antibodies to

human Fc receptor. The cells were then stained with anti-IFNγ antibodies (BD Bioscience, USA)

for 30 min at 4 °C. After staining, all samples were washed twice with phosphate buffered saline

(PBS) containing 0.1% saponin, 0.1% BSA and 0.05% NaN_3 (Sigma-Aldrich, USA), and

resuspended in 300 μL PBS for measurement in a flow cytometer (FACSVerse™ flow cytometry,

BD Bioscience, USA).

Real-time reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2

Throat, sputum and blood samples were collected for extracting SARS-CoV-2 RNA from

hypertensive patients suspected of having SARS-CoV-2 infection. In brief, RNA was extracted

within 2 h using the total RNA isolation kit. Cell lysates (250 μL) were transferred into a

collection tube followed by vortex for 10 s. After standing at room temperature for 10 min, the

collection tube was centrifugated at 1000 rpm for 5 min. The suspension was used for RT-PCR

assay of SARS-CoV-2 RNA. Two target genes, including open reading frame 1ab (ORF1ab) and

nucleocapsid protein (N), were simultaneously amplified and tested during the RT-PCR assay.

The sequences of primers and probes were: Target 1 (ORF1ab): forward primer

CCCTGTGGGTTTTACACTTAA; reverse primer ACGATTGTGCATCAGCTGA; and the probe

5′-VIC-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3′. Target 2 (N): forward primer

GGGGAACTTCTCCTGCTAGAAT; reverse primer CAGACATTTTGCTCTCAAGCTG; and

the probe 5′-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3′. The RT-PCR assay was

performed using a SARS-CoV-2 nucleic acid detection kit. Reaction mixture contained 12 μL of

reaction buffer, 4 μL of enzyme solution, 4 μL of probe primer solution, 3 μL of diethyl

pyrocarbonate–treated water, and 2 μL of RNA template. The RT-PCR assay was performed

under the following conditions: incubation at 50 °C for 15 min and 95 °C for 5 min, 40 cycles of

denaturation at 94 °C for 15 s, and extending and collecting fluorescence signal at 55 °C for 45 s.

A cycle threshold value (C_t-value) less than 37 was defined as a positive test result, and a C_t-value

of 40 or more was defined as a negative test. These diagnostic criteria were based on the

recommendation by the National Institute for Viral Disease Control and Prevention (China).

Samples with a C_t-value of 37 to less than 40 was confirmation by retesting. The copies of RNA

per reaction were obtained from the standard curve of limiting-dilution series of standard copies of

RNA versus PCR amplification cycle.

Enzyme-linked immunosorbent assay (ELISA) of immunoglobulin (Ig)

Antibodies (IgM, IgA, and IgG) specific to SARS-CoV-2 were determined with two different

ELISA: an in-house assay using SARS-CoV-2 Receptor Binding Domain (RBD) protein (Cat.

#Z03479, Genscript Biotech, USA) as an antigen, or a commercial kit (SARS-CoV-2 Spike RBD

ELISA Kit, Cat. #40591-V08H, Sino Biological, China). Microtiter plates were coated with 50

ng/well of target protein overnight at 4 °C. Plates were then blocked for 2 h at 37 °C using 200 μL

of 5% non-fat milk in PBS. Serum samples were then diluted into 1:50 using PBS and 100 μL of

each sample was applied to coated ELISA plate and incubated for 2 h at 37 °C. Plates were then

washed with PBS and incubated with HRP-labeled anti-human IgM, IgA, and IgG (Sigma Aldrich,

USA), which were diluted to 1:2000 in 5% non-fat milk in PBS. After incubation for another 1 h

at room temperature, the plates were washed and developed with TMB/E substrate (Millipore,

USA). Finally, the reaction was stopped with 1 M H_2SO_4, and the optical density (OD) at 450 nm

was measured. Negative serum control was run each time when the assay was performed. A

sample is positive if its adjusted OD value (OD of test – OD of control) exceeds the mean plus 3

standard deviations of the normal controls.

Flow cytometry analysis

All samples were analyzed by FACSVerse™ flow cytometry (BD Bioscience, USA). Two blood

samples in two tubes (100 μL each) were stained according to the manufacturer's instructions.

Then, red-cell lysis buffer (1 mL) was added to each tube, the samples were incubated for 10 min

and washed with Sorvall cell washer (Thermo Fisher Scientific, USA). Cells were blocked with

FcR blocking reagent (Meltenyi Biotec, USA) for 30 min at 4 °C to reduce nonspecific binding of

antibodies to human Fc receptor and washed with PBS. The cells were then stained with

antibodies as listed in Figure and the fixable dead cell stain kit (Invitrogen, USA) for 30 min at

4 °C and were then resuspended in 350 μL PBS and analyzed in flow cytometry (FACSVerse™

flow cytometry, BD Bioscience, USA). Calibration and quality control for the instrument were

carried out daily with the use of eight-color setup beads (BD Bioscience). All specimens were

analyzed in duplicates with coefficient of variation (CV) < 5% by two independent technicians

under the inter-laboratory quality control. The experiments were repeated if the results showed

CV > 5% according to the instructions of BD Bioscience. The data were analyzed by FlowJo

software (version 10, Tree Star, USA).

Statistical analysis

Categorical variables were described as frequency rates and percentages, and continuous variables

were described using mean and median values. Means for continuous variables were compared

using independent group *t* tests when the data were normally distributed; otherwise, the

Mann-Whitney test was used. Data (non-normal distribution) from repeated measures were

compared using the generalized linear mixed model. Proportions for categorical variables were

compared using the χ^2 test, although the Fisher's exact test was used when the data were limited.

All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences

Inc., version 13.0). For unadjusted comparisons, a two-sided P value less than 0.05 was

considered statistically significant. The analyses have not been adjusted for multiple comparisons

and, given the potential for type I error, the findings should be interpreted as exploratory and

descriptive. Because the cohort of patients in our study was not derived from random selection, all

statistics are deemed to be descriptive only.